Advertisement

Journal of Medical Toxicology

, Volume 8, Issue 2, pp 118–123 | Cite as

Mortality Predictors of Snake Bite Envenomation in Southern India—A Ten-Year Retrospective Audit of 533 Patients

  • Suresh DavidEmail author
  • Sarah Matathia
  • Solomon Christopher
Toxicology Investigation

Abstract

Snake bite incidence is highest in Asia and sub-Saharan Africa. This retrospective audit of 533 adult patients, who had presented to the Emergency Department, collates clinical features, effect of pharmacologic interventions and the risk factors that influence morbidity and mortality. Dual toxicity, neurological and haematological, was observed in 30.4% of patients. Laboratory evidence of haematotoxicity was demonstrated in 314 (58.9%) and 40% demonstrated clinical evidence of bleeding. However, 7.3% of these patients did not have laboratory evidence of bleeding disorder (p < 0.001). Conversely, 60% did not have clinical evidence of bleeding, but demonstrated laboratory evidence of abnormal parameters. Acute kidney injury (AKI) was evident in 28% of patients and 15.3% required haemodialysis. About 25% with no haematotoxicity showed evidence of AKI. The majority received 6–12 vials of poly-valent anti-snake venom. Hypersensitivity reaction rate was 8% and predominantly anaphylactoid in nature. The length of hospital stay ranged from 2 to 28 days and 20% required mechanical ventilation. Overall mortality rate was 7.5% with significant association to AKI, haematotoxicity and assisted ventilation. The mortality rate was 18% in patients with pre-hospital delay more than 24 h, as against 5% when admitted within the above specified period (p = <0.001). The strength of this study is the accrued information of over a period of 10 years of snake-bite management through the Emergency Department of a university hospital setting. The limitations are the retrospective study design and the rejection percentage of 15.5% due to insufficient information from the total chart pool.

Keywords

Snake bite Polyvalent ASV Anti-snake venom Mortality 

Introduction

Snake bite injury data published by the World Health Organization estimates an incidence of five million snakebite cases worldwide each year. Reportedly, about 200,000 persons fall prey to snake bite per year in India and 50,000 of them die every year [1]. The highest incidence of snake bites is in South Asia, Southeast Asia and sub-Saharan Africa and caused by elapids (cobras, kraits, mambas, etc.) and vipers, and in some regions, sea snakes. This retrospective analysis of a decade of information collected from a University teaching hospital was intended for comprehensive understanding of the epidemiologic and clinical features of snake bite envenomation in South India.

Aims and Objectives

  • ▪ To study the epidemiology, and the effect of pharmacologic interventions pertaining to snake bite

  • ▪ To analyse the association between various risk factors and their influence on the final outcome

Study Design

Retrospective chart review

Study Population

All patients were 18 years and older who had presented to the Emergency Department with history of snake bite over a period of 10 years, 1997–2007.

Exclusion Criteria

None.

Outcome measures:
  1. 1.

    Mortality: Died prior to discharge from hospital

     
  2. 2.

    Morbidity: Renal dysfunction, tissue loss, limb amputation, etc.

     
  3. 3.

    Length of stay: Number of days admitted to the hospital

     

Methodology

Relevant data were collected from medical records of the study population on the Chart Review Forms. Details included Epidemiologic Information, snake bite details, symptomatology and resuscitation requirements, in addition to indications for anti-snake venom (ASV) administration, based on clinical and laboratory investigations. The patient’s progress was followed through the entire period of hospital stay and the outcome documented.

Ethical Considerations

None. All patient identification will be de-identified per protocol to comply with research standards.

Sample Collection

The sample size of 533 patients was derived from a total number of 628 charts (Fig. 1). Statistical analyses were performed using SPSS 11.0 for windows. Comparisons of continuous variables were assessed using t test and categorical variables were analysed using chi-square test. Variables that were significantly related to mortality at the univariate analyses (p < 0.1) were included in a multivariable logistic regression model. Unadjusted and adjusted odds ratios are presented for all the risk factors for mortality.
Fig. 1

Sample size derivation

Results

The demography of the study population, bite site, clinical findings, investigations, toxicity and ASV reactions in addition to the final outcome are depicted in Table 1. Snake bite was noted pre-dominantly in the rural agricultural population of India, with male predominance. The main species which had been identified in the study area are Russell’s viper (Daboia russelii), Common Cobra (Naja naja) and Common Krait (Bungarus caeruleus). The bite environment was recorded in 43% of cases and it occurred outdoors—while working or sleeping in the open, during summer months. Seasonal variation similar to our observation has been noted elsewhere [2] with the predominant incidence being in the rainy season—June to September (Fig. 2).
Table 1

Baseline characteristics

Demography

Age (years)

32 ± 15.9

Male

370 (69.4%)

Hospitalisation within 24 h

409 (76.7%)

Bite site

Upper limb

111

Lower limb

382

Trunk and head

20

Clinical Findings

Heart rate/min

93.6 ± 21.3

Mean systolic pressure—mmHg

93.8 ± 15.6

Respiratory rate/min

25.5 ± 7.7

Abnormal pulse-oximetry %

86 (16.1%)

Loss of consciousness

87 (16.3%)

Vomiting

195 (36.6%)

Ptosis

332 (62.3%)

Diplopia

92 (17.3%)

Ophthalmoplegia

134 (25.1%)

Dyspnoea

146 (27.4%)

Dysarthria

74 (13.9%)

Muscle weakness

145 (27.2%)

Bleeding at bite site

142 (26.6%)

Laboratory Findings

Haematuria

92 (17.3%)

Prolonged PT

253 (47.5%)

Prolonged INR

198 (37.1%)

Prolonged PTT

173 (32.5%)

Leucocytosis

16.1 (1.1–72.8)

Toxicity

 

Nil

26

Haemato-toxicity

152

Neurotoxicity

193

Dual toxicity

162

Management

ASV Reaction

 

41 (7.7%)

Anaphylaxis

12 (2.3%)

Anaphylactoid reactions

29 (5.4%)

Nil reaction

491 (92.3)

Mechanical ventilation

105 (19.7%)

Inotrope support

48 (9%)

Blood transfusion

42 (7.9%)

FFP transfusion

45 (8.4%)

Surgical intervention

19 (3.6)

Outcome

Non-envenomated cases

59 (11.064%)

Acute kidney injury

143 (26.8%)

Mortality

40 (7.5)

Mean length of hospital stay (days)

4 (1–70)

Fig. 2

Seasonal variation in snake bite incidence

Bite site was mostly in the lower limbs. Although about one fourth of the patients or their relatives volunteered to identify the species of the snake, its reliability, however, could not be confirmed. About three fourth of the patients sought first aid in local clinics and peripheral hospitals prior to definitive treatment in the University hospital (research setting). Most of the cases were admitted within 24 h of the bite. Morbidity included cellulitis, neurotoxicity and haematotoxicity. Dual toxicity was observed in 30.4% of patients.

About 40% demonstrated clinical evidence of bleeding. However, 7.3% of these patients did not have laboratory evidence of bleeding disorder. This is statistically significant (p < 0.001). Conversely, 60% of patients did not have clinical evidence of bleeding, but demonstrated laboratory evidence of abnormal parameters. Laboratory evidence of acute renal failure was noted in 28% of patients with clinical signs of haematotoxicity and 15.3% required haemodialysis. Laboratory evidence of haematotoxicity (defined in our study as any of the following: PT > 13.2 s, PTT > 37.2 s, CT > 20 min and BT > 7 min) was demonstrated by 314 patients (58.9%). About 25% with no haematotoxicity showed evidence of abnormal renal function. Abnormal platelet count (defined in our study as <60,000) was noted in 16% and about 81% demonstrated leucocytosis (WBC > 20,000), ranging up to 40,000/mm3.

All the 533 cases received polyvalent ASV which is effective against all the four common species, which are as follows: Russells viper (D. russelii), Common Cobra (N. naja), Common Krait (B. caeruleus) and Saw Scaled viper (Echis carinatus). There are no currently available monovalent ASVs primarily because there are no objective means of identifying the snake species, in the absence of the dead snake. It would be impossible for the physician to determine which type of monovalent ASV to employ in treating the patient. The hypersensitivity reaction rate was about 8% and was predominantly minor anaphylactoid in nature—pruritus, hypotension, urticarial rash, syncope, fever, etc. Dosage data were available for 517 patients and the majority received 6–12 vials of ASV (Fig. 3). About 9% of the patients required inotropic support and 8% needed blood transfusion. Fresh frozen plasma was needed in 8% of patients. Tetanus toxoid was administered in 95% of patients. Surgical intervention included debridement with skin or flap cover, incision and drainage. One patient required amputation.
Fig. 3

Anti-snake venom therapy in the setting of the study

Admission to the intensive care unit was required in 40% of the total population. About 20% required mechanical ventilation, which extended up to 10 days (Fig. 4). The indications were respiratory insufficiency, due to neuro-toxicity. Of these, 33% expired. Of the remaining patients who did not require the same, 1.5% died, thus demonstrating statistical significance in mortality in relationship with assisted ventilation (p = <0.001). Length of hospital stay ranged from 2 to 28 days (Fig. 5). Morbidity included renal failure, intra-cranial bleeds, post-anoxic encephalopathy, limb contractures, acute coronary syndrome, amputations, etc. (Table 2). The overall mortality rate was 7.5%. Multiple logistic regression analysis on all factors which influenced mortality at the univariate level demonstrated a significant association between acute kidney injury (AKI), haematotoxicity and assisted ventilation with respect to mortality. Patients with AKI demonstrated a mortality of 21% as against 3% of those who died and did not have AKI (p = <0.001).
Fig. 4

Hours of ventilation in the ICU

Fig. 5

Length of hospital stay (in days)

Table 2

Risk factors and morbidity profile due to snake bite

Risk factors

Mortality

Odds ratio

Alive

Dead

Unadjusted

Adjusted

Acute renal failure

113 (22.9%)

30 (75%)

10.1

5.2a

Hospitalization within 24 h

389 (80.9%)

20 (50%)

4.2

1.1

Ventilation

71 (14.4%)

34 (85%)

33.7

46.7a

Presence of haematotoxicity

27 (5.5%)

19 (47.5%)

15.6

2.8

Platelets < 60

25 (6.8%)

14 (41.2%)

12.1

5.1

60–100

19 (5.2%)

5 (14.7%)

5.7

1.8

>100b

323 (88%)

15 (44.1%)

  

WBC ≤ 11,000

93 (21.6%)

7 (18.9%)

1.2

0.9

aStatistically significant at 5% α level

bReference category

Age group analysis demonstrated maximum mortality in patients above 65 (20%) and <10 years (11%), thereby including the extremes of age. There was no association age and delay to presentation against intubation and acute kidney injury. Patients in whom there was pre-hospital delay more than 24 h, the mortality was 18% as against 5% in those who were admitted within the above specified period (p = <0.001). Significant statistical relationship (p = <0.001) was observed in the total number of 20 patients (23%) who presented with loss of consciousness at the time of presentation to the Emergency Department who expired subsequently.

Discussion

The strength of this study is the accrued information available over a decade of snake bite management in a university hospital setting, which endeavours to practice evidence-based medicine. India remains amongst the group of countries with the highest mortality [3]. Globally, usage of monovalent ASV is the preferred mode of treatment. However, In India and the neighbouring countries, due to the usage of polyvalent vaccine, species identification is not of critical clinical value. Snake identification was recorded in one fourth of the subjects, since visibility and fear were significant obstacles, as observed elsewhere [2]. This impedes the investigation of the epidemiology of species-specific biological behaviour of envenomation. Further, species that dominate the snake bite population differ according to geography [4, 5]. Of recent interest is the discovery of another species, the hump-nosed pit viper (Hypnale hypnale), also capable of causing lethal envenomation [6]. This necessitates the development of a more inclusive polyvalent vaccine, since the present drug is exclusively for the Indian cobra (N. naja), the common krait (B. caeruleus), the Russell’s viper (D. russelii) and the saw-scaled viper (E. carinatus).

One of the challenges in envenomation medicine is the inability to quantify venom dose, thus making treatment protocols arbitrary. The quantity of venom that can be extracted from the Russell’s viper varies significantly and depends on the size of the snake [7]. The range of venom injected was shown to be 5–147 mg. This would imply a maximum ASV dose of around 25 vials [8]. ASV is an expensive commodity and is of perennial short supply. Therefore it needs to be used judiciously. Randomised control trials in two independent settings which administered high dose ASV to one study arm and low dose ASV to the other, concluded that there was no statistical difference between the two arms in terms of mortality, length of stay or supportive measures [9, 10]. Dosage requirements and recommendations have varied significantly—from an average of 51.2 vials for cobra bites and 31 vials for viper bites [11]. Guidelines based on Russell’s Viper venom recommended the administration of 10 units of ASV, and only if the patient exhibits signs or symptoms of systemic or severe local envenomation [12]. The biological behaviour and benefit of low-dose ASV therapy have been observed to exhibit an overall mortality rate of 7.5%, following the low-dose protocol. This is encouraging and provides the impetus for further investigation. One particular study of 277 cases of snake bite envenomation examined predictors of mortality—vomiting (RR—0.51), neurotoxicity (RR—3.15) and creatinine elevation (RR—1.35) [13]. This study also indicated that acute renal failure and the need for ventilation bear significance in predicting mortality.

It has been recommended by the WHO in 2005 that snake bite should be formally recognised as an important occupational disease and should be made a specific notifiable disease in all countries in the South East Asian region [14]. It is also recommended that education and training on snake bite should be included in the curriculum of medical schools. This study has indicated that bites were more common when working and sleeping outdoors. Therefore, there is significant scope for public health intervention, i.e. community education, awareness about snake bite, wearing shoes and sleeping indoors as an effective method to mitigate the consequences of envenomation.

This retrospective chart review has its limitations since the retrospective information gleaned was from 533 patients over 10 years, with a rejection percentage of 15.5% due to insufficient information from the total chart pool. Moreover, the selection bias due to a single-centre data is justifiable. Furthermore, no prior baseline information about the study population was available. For example, anaemia was noted in one third of the study population. However, no conclusion could be drawn from this observation, since their baseline haemoglobin is unknown.

Wound aspirate, serum and urine can be subjected to enzyme-linked immunoassay (ELISA) and radioimmunoassay for detection of snake venom and venom antibodies [15]. They can detect values as low as 0.5 ng of venom. Current ELISA systems involving snake venoms have low specificity, and most cannot reliably differentiate venoms of related snakes. Nonspecific reactions and cross-reactivity are unacceptably high. However, there is scope for further development in this field.

Conclusion

Published literature depicts significant variation that exists between regions of India and in the Asian sub-continent. There is dearth of collective evidence for clear pathways to be determined to predict the outcome of snake envenomation in the above geographical area. The objective of this exercise—the largest case series of its kind—was to collate a decade of experience from best practice standards of a University teaching medical institute of repute, to facilitate comprehensive understanding of the disease behaviour and to refine patient care guidelines.

References

  1. 1.
  2. 2.
    Brunda G, Sashidhar RB (2007) Epidemiological profile of snake-bite cases from Andhra Pradesh using immunoanalytical approach. I. Indian J Med Res 125(5):661–668PubMedGoogle Scholar
  3. 3.
    Simpson ID (2007) Snakebite management in India, the first few hours: a guide for primary care physicians. J Indian Med Assoc 105(6):324–326PubMedGoogle Scholar
  4. 4.
    Kirte RC, Wahab SN, Bhathkule PR (2006) Record based study of snake bite cases admitted at Shri Vasantrao Naik Government Medical College & Hospital, Yavatmal (Maharashtra). Indian J Publ Health 50(1):35–37Google Scholar
  5. 5.
    Bhardwaj A, Sokhey J (1998) Snake bites in the hills of north India. Nat Med J India 11(6):264–265Google Scholar
  6. 6.
    Simpson ID, Norris RL (2007) Snakes of medical importance in India: is the concept of the “Big 4” still relevant and useful? Wilderness Environ Med 18(1):2–9PubMedCrossRefGoogle Scholar
  7. 7.
    Tun P, Cho KA (1986) Amount of venom injected by Russell’s viper (Vipera russelli). Toxicon 24(7):730–733PubMedCrossRefGoogle Scholar
  8. 8.
    Simpson ID (2007) The paediatric management of snakebite: the National Protocol. Ind Ped 44(3):173–176Google Scholar
  9. 9.
    Paul V, Pratibha S, Prahlad KA et al (2004) High-dose anti-snake venom versus low-dose anti-snake venom in the treatment of poisonous snake bites—a critical study. J Assoc Phys India 52:14–17Google Scholar
  10. 10.
    Tariang DD, Philip PJ, Alexander G, Macaden S, Jeyaseelan L, Peter JV, Cherian AM (1999) Randomized controlled trial on the effective dose of anti-snake venom in cases of snake bite with systemic envenomation. J Assoc Phys India 47(4):369–371Google Scholar
  11. 11.
    Bawaskar HS, Bawaskar PH, Punde DP, Inamdar MK, Dongare RB, Bhoite RR (2008) Profile of snakebite envenoming in rural Maharashtra, India. J Assoc Phys India 56:88–95Google Scholar
  12. 12.
    Ghosh S, Maisnam I, Murmu BK, Mitra PK, Roy A, Simpson ID (2008) A locally developed snakebite management protocol significantly reduces overall anti-snake venom utilization in West Bengal, India. Wilderness Environ Med 19(4):267–274PubMedCrossRefGoogle Scholar
  13. 13.
    Kalantri S, Singh A, Joshi R, Malamba S, Ho C, Ezoua J, Morgan M (2006) Clinical predictors of in-hospital mortality in patients with snake bite: a retrospective study from a rural hospital in central India. Trop Med Int Health 11(1):22–30PubMedCrossRefGoogle Scholar
  14. 14.
    David AW (2005) Guidelines for the clinical management of snake-bites in the south-east Asia region. World Health Organization, Regional Office for South East Asia, New Delhi pp 1–67. http://www.searo.who.int/LinkFiles/SDE_mgmt_snake-bite.pdf. Last accessed on June 15, 2010
  15. 15.
    Selvanayagam ZE, Gopalakrishnakone P (1999) Tests for detection of snake venoms, toxins and venom antibodies: review on recent trends (1987–1997). Toxicon 37(4):565–586PubMedCrossRefGoogle Scholar

Copyright information

© American College of Medical Toxicology 2012

Authors and Affiliations

  • Suresh David
    • 1
    Email author
  • Sarah Matathia
    • 2
  • Solomon Christopher
    • 3
  1. 1.Department of Emergency MedicineChristian Medical CollegeVelloreIndia
  2. 2.University of CaliforniaSan FranciscoUSA
  3. 3.Department of Clinical EpidemiologyChristian Medical CollegeVelloreIndia

Personalised recommendations